

**Question for written answer E-005199/2020
to the Commission**

Rule 138

Christophe Hansen (PPE)

Subject: Funding for research into dementia

Dementia affects almost 8 million people in the European Union and the number is expected to double by 2050. There is currently no cure for dementia, no disease-modifying treatment, and only four symptom-modifying drugs on the market.

As such, research into new ways of diagnosing, treating and supporting people with dementia is vitally important.

How much money was allocated to dementia and Alzheimer's research projects as part of Horizon 2020, and will this lead to an increase, decrease or plateau in the funding for dementia and Alzheimer's research in the forthcoming Horizon Europe research programme?

Will research into dementia and Alzheimer's disease be made a specific priority of the Horizon Europe research programme?

Does the Commission believe that dementia should be prioritised as a future mission, much as cancer was?